{"id":"W2923800831","doi":"10.1186/s13058-019-1115-2","title":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; Eisai; MacroGenics; Puma Biotechnology; Daiichi-Sankyo; Teva Pharmaceutical Industries; Wyeth; Sanofi; GlaxoSmithKline; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Neratinib; Placebo; Surgical oncology; Double blind; Medicine; Randomized controlled trial; Oncology; Internal medicine; Breast cancer; Alternative medicine; Pathology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005275469,0.0003626295,0.001760804,0.0006507475,0.0005584953,0.0005391776,0.0004852304,0.00018001,0.006976122],"category_scores_gemma":[0.0001618576,0.0002037492,0.0003818018,0.00208095,0.0007257343,0.0002138248,0.0002172213,0.001324587,0.0001181162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003548395,"about_ca_system_score_gemma":0.001541002,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02531151,"about_ca_topic_score_gemma":0.006862377,"domain_scores_codex":[0.9938304,0.0008216854,0.0007747349,0.001005881,0.002566608,0.00100072],"domain_scores_gemma":[0.994103,0.002761744,0.0001658376,0.001294872,0.001132804,0.0005417325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.983947,0.0003584715,0.001707313,0.00003545303,0.003633748,0.00003250602,0.0006455376,0.0003595319,0.0004550337,0.0006590045,0.001521117,0.006645269],"study_design_scores_gemma":[0.9858366,0.0007133361,0.0004377747,0.000170945,0.001409381,0.00003691555,0.000368807,0.008643086,0.0002057849,0.0001229323,0.001817639,0.0002367611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9613961,0.002537505,0.0002299338,0.01674165,0.0001993261,0.01446908,0.0004304521,0.00005801007,0.003937947],"genre_scores_gemma":[0.9807453,0.0008635253,0.0001531819,0.0003432578,0.001720432,0.007296481,0.0002052535,0.00007475121,0.008597828],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0193492,"threshold_uncertainty_score":0.9939317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0792212121238377,"score_gpt":0.436616696189183,"score_spread":0.3573954840653453,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}